Since the expression of PUMA and BIM can be suppressed by epigenetic modifications, drugs that target epigenetic regulators, such as HDAC inhibitors, might be beneficial for upregulating these initiators of apoptosis, thereby increasing the effectiveness of anti-cancer therapy [233, 234]. Here, BCL2L11 is linked to cancer.